NCT01669876

Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease

3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 85 (actual)
• Sponsor: Rock Creek Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 65 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

To explore whether dietary supplementation with a version of Anatabloc(R) exerts an effect on blood levels of amyloid beta (Aβ), or impacts global or functional measures of Alzheimer's Disease (AD) in subjects with mild to moderate AD.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Anatabloc(R)	Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
DIETARY_SUPPLEMENT	Placebo	Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day

Timeline

• Start date: 2012-08-01
• Primary completion: 2014-12-01
• Completion: 2015-02-01
• First posted: 2012-08-21
• Last updated: 2015-04-30

Locations

1 site across 1 country: United States